105 related articles for article (PubMed ID: 19632790)
1. A novel immunotherapy to hepatocellular carcinoma: CD40-activated B lymphocytes transfected with AFPmRNA.
Wan Y; Ma X; Li X; Yi J
Med Hypotheses; 2009 Nov; 73(5):835-7. PubMed ID: 19632790
[TBL] [Abstract][Full Text] [Related]
2. Autogeneic rna-electroporated CD40-ligand activated b-cells from hepatocellular carcinoma patients induce CD8+ T-cell responses ex vivo.
Shen S; Xu Z; Qian X; Ding Y; Yu L; Liu B
Exp Oncol; 2007 Jun; 29(2):137-43. PubMed ID: 17704747
[TBL] [Abstract][Full Text] [Related]
3. RNA-electroporated CD40-activated B cells induce functional T-cell responses against HepG2 cells.
Shen SN; Xu Z; Qian XP; Ding YT; Yu LX; Liu BR
Eur J Cancer Care (Engl); 2008 Jul; 17(4):404-11. PubMed ID: 18485013
[TBL] [Abstract][Full Text] [Related]
4. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
[TBL] [Abstract][Full Text] [Related]
5. Induction of myeloma-specific cytotoxic T lymphocytes ex vivo by CD40-activated B cells loaded with myeloma tumor antigens.
Kim SK; Nguyen Pham TN; Nguyen Hoang TM; Kang HK; Jin CJ; Nam JH; Chung SY; Choi SJ; Yang DH; Kim YK; Chung IJ; Kim HJ; Lee JJ
Ann Hematol; 2009 Nov; 88(11):1113-23. PubMed ID: 19277657
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cells pulsed with alpha-fetoprotein and mutant P53 fused gene induce bi-targeted cytotoxic T lymphocyte response against hepatic carcinoma.
Ren J; Jia J; Zhang H; Zhang L; Ma B; Jiang H; Di L; Song G; Yu J
Cancer Sci; 2008 Jul; 99(7):1420-6. PubMed ID: 18422751
[TBL] [Abstract][Full Text] [Related]
7. Induction of alpha-fetoprotein-specific CD4- and CD8-mediated T-cell response using RNA-transfected dendritic cells.
Zhang HM; Zhang LW; Ren J; Fan L; Si XM; Liu WC
Cell Immunol; 2006 Feb; 239(2):144-50. PubMed ID: 16814271
[TBL] [Abstract][Full Text] [Related]
8. B-cell expansion in the presence of the novel 293-CD40L-sCD40L cell line allows the generation of large numbers of efficient xenoantigen-free APC.
Ivanov R; Aarts T; Hagenbeek A; Hol S; Ebeling S
Cytotherapy; 2005; 7(1):62-73. PubMed ID: 16040385
[TBL] [Abstract][Full Text] [Related]
9. RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma.
Mason NJ; Coughlin CM; Overley B; Cohen JN; Mitchell EL; Colligon TA; Clifford CA; Zurbriggen A; Sorenmo KU; Vonderheide RH
Gene Ther; 2008 Jul; 15(13):955-65. PubMed ID: 18337841
[TBL] [Abstract][Full Text] [Related]
10. CD40 ligand is essential for generation of specific cytotoxic T cell responses in RNA-pulsed dendritic cell immunotherapy.
Onaitis MW; Kalady MF; Emani S; Abdel-Wahab Z; Tyler DS; Pruitt SK
Surgery; 2003 Aug; 134(2):300-5. PubMed ID: 12947333
[TBL] [Abstract][Full Text] [Related]
11. alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination.
Meng WS; Butterfield LH; Ribas A; Dissette VB; Heller JB; Miranda GA; Glaspy JA; McBride WH; Economou JS
Cancer Res; 2001 Dec; 61(24):8782-6. PubMed ID: 11751399
[TBL] [Abstract][Full Text] [Related]
12. A membrane-bound form of IL-4 enhances proliferation and antigen presentation of CD40-activated human B cells.
Park JY; Yoon SH; Kim EK; Yun SO; Park MY; Sohn HJ; Kim TG
Immunol Lett; 2008 Feb; 116(1):33-40. PubMed ID: 18096249
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor effects of immunotherapeutic peptide on the treatment of hepatocellular carcinoma with HBc carrier.
Kong J; Diao Z; Deng X; Zhong H; Yao W; Hu X
Oncol Rep; 2007 Jul; 18(1):279-85. PubMed ID: 17549380
[TBL] [Abstract][Full Text] [Related]
14. Patient-derived dendritic cells transduced with an a-fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells.
González-Carmona MA; Märten A; Hoffmann P; Schneider C; Sievers E; Schmidt-Wolf IG; Sauerbruch T; Caselmann WH
Liver Int; 2006 Apr; 26(3):369-79. PubMed ID: 16584401
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of DC fused with tumor cells or transfected with tumor total RNA as potential cancer vaccines against hepatocellular carcinoma.
Zhang HM; Zhang LW; Liu WC; Cheng J; Si XM; Ren J
Cytotherapy; 2006; 8(6):580-8. PubMed ID: 17148035
[TBL] [Abstract][Full Text] [Related]
16. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K
Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333
[TBL] [Abstract][Full Text] [Related]
17. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy.
Diehl L; den Boer AT; Schoenberger SP; van der Voort EI; Schumacher TN; Melief CJ; Offringa R; Toes RE
Nat Med; 1999 Jul; 5(7):774-9. PubMed ID: 10395322
[TBL] [Abstract][Full Text] [Related]
18. Specific antihepatocellular carcinoma T cells generated by dendritic cells pulsed with hepatocellular carcinoma cell line HepG2 total RNA.
Zhang L; Zhang H; Liu W; Wang H; Jia J; Si X; Ren J
Cell Immunol; 2005 Nov; 238(1):61-6. PubMed ID: 16472793
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of hepatocellular carcinoma with a vaccine based on xenogeneic homologous alpha fetoprotein in mice.
Zhang W; Liu J; Wu Y; Xiao F; Wang Y; Wang R; Yang H; Wang G; Yang J; Deng H; Li J; Wen Y; Wei Y
Biochem Biophys Res Commun; 2008 Nov; 376(1):10-4. PubMed ID: 18725206
[TBL] [Abstract][Full Text] [Related]
20. Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma.
Vollmer CM; Eilber FC; Butterfield LH; Ribas A; Dissette VB; Koh A; Montejo LD; Lee MC; Andrews KJ; McBride WH; Glaspy JA; Economou JS
Cancer Res; 1999 Jul; 59(13):3064-7. PubMed ID: 10397245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
